<unk>  is conventionally treated with intravitreal injections of angiogenesis inhibitors (also known as "anti-VEGF" drugs) to control neovascularization and reduce the area of fluid below the retinal pigment epithelium. Angiogenesis inhibitors include pegaptanib, ranibizumab and bevacizumab (known by a variety of trade names, such as Macugen, Avastin or Lucentis). These inhibitors slow or stop the formation of new blood vessels (angiogenesis), typically by binding to or deactivating the transmission of vascular endothelial growth factor ('VEGF'), a signal protein produced by cells to stimulate formation of new blood vessels. The effectiveness of angiogenesis inhibitors has been shown to significantly improve visual prognosis with<unk> , the recurrence rate for these neovascular areas remains high.<unk>  may also be treated with photodynamic therapy (PDT) coupled with a photosensitive drug such as verteporfin (Visudyne). The drug is given intravenously. It is then activated in the eye by a laser light. The drug destroys the new blood vessels, and prevents any new vessels forming by forming thrombi. A Cochrane Review published in 2016 found that people with severe myopia (short-sightedness or near-sightedness) may benefit from being given anti-VEGF treatment.
Choroidal neovascularization
Intraretinal microvascular abnormalities
Pachychoroid disorders of the macula
Macular scarring
Corneal neovascularization
Retinal vasculitis
Punctate inner choroiditis
Progressive outer retinal necrosis